CSF neurogranin or tau distinguish typical and atypical Alzheimer disease
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Objective: To assess whether high levels of cerebrospinal fluid neurogranin are found in atypical as well as typical Alzheimer's disease. Methods: Immunoassays were used to measure cerebrospinal fluid neurogranin in 114 participants including healthy controls (n = 27), biomarker‐proven amnestic Alzheimer's disease (n = 68), and the atypical visual variant of Alzheimer's (n = 19) according to international criteria. CSF total‐tau, Aβ42, and neurofilament light concentrations were investigated using commercially available assays. All affected individuals had T1‐weighted volumetric MR images available for analysis of whole and regional brain volumes. Associations between neurogranin, brain volumes, total‐tau, Aβ42, and neurofilament light were assessed. Results: Median cerebrospinal fluid neurogranin concentrations were higher in typical and atypical Alzheimer's compared to controls (P < 0.001 and P = 0.005). Both neurogranin and total‐tau concentrations, but not neurofilament light and Aβ42, were higher in typical Alzheimer's compared to atypical patients (P = 0.004 and P = 0.03). There were significant differences in the left hippocampus and right and left superior parietal lobules in atypical patients, which were larger (P = 0.03) and smaller (P = 0.001 and P < 0.001), respectively, compared to typical patients. We found no evidence of associations between neurogranin and brain volumes but a strong association with total‐tau (P < 0.001) and a weaker association with neurofilament light (P = 0.005). Interpretation: These results show significant differences in neurogranin and total‐tau between typical and atypical patients, which may relate to factors other than disease topography. The differential relationships between neurogranin, total‐tau and neurofilament light in the Alzheimer's variants, provide evidence for mechanistically distinct and coupled markers of neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“A standardized protocol for the collection and storage of CSF was followed.(21) Briefly, CSF was collected in sterile polypropylene tubes, centrifuged at 4000 rpm for 10 min at +40°C.”
MethodSelf-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Self-citationConsensus classification of posterior cortical atrophy
Crutch, S. J., Schott, J. M., Rabinovici, G. D., Murray, M., Snowden, J. S., van der Flier, W. M., Dickerson, B. C., Vandenberghe, R., Ahmed, S., Bak, T. H., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.014 · Cited by 665
Self-citationPhysiological release of endogenous tau is stimulated by neuronal activity
Pooler, A. M., Phillips, E. C., Lau, D. H. W., Noble, W., & Hanger, D. P. (2013) · The EMBO Reports · doi:10.1038/embor.2013.15 · Cited by 642 · cited 1×
“However, it is becoming apparent that tau may not be a simple damage biomarker, but is secreted from cells under physiological conditions, a process which is regulated by neuronal activity.(34,35)NFL is a marker of large fiber myelinated axonal degeneration,(36) is elevated in neurodegeneration independent of amyloid…”
BackgroundZetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3037 · Cited by 487
Self-citationTotal and phosphorylated tau protein as biological markers of Alzheimer’s disease
Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389
Self-citationCerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease
Portelius, E., Zetterberg, H., Skillbäck, T., Törnqvist, U., Andreasson, U., Trojanowski, J. Q., Weiner, M. W., Shaw, L. M., & Mattsson, N. (2015) · Brain · doi:10.1093/brain/awv267 · Cited by 279
Self-citationNeurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease
Kester, M. I., Teunissen, C. E., Crimmins, D. L., Herries, E. M., Ladenson, J. H., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1867 · Cited by 246
Increased CSF neurogranin concentration is specific to Alzheimer disease
Wellington, H., Paterson, R. W., Portelius, E., Törnqvist, U., Magdalinou, N., Fox, N. C., Blennow, K., Schott, J. M., & Zetterberg, H. (2016) · Neurology · doi:10.1212/wnl.0000000000002423 · Cited by 232 · cited 2×
“43 samples were run on an MSD platform (Meso Scale Discovery, Rockville, MD, USA), including amnestic AD (n = 19), PCA (n = 5) and controls (n = 19), to measure CSF Ng, as previously described.(9) The monoclonal antibody Ng7, which recognizes the C-terminus of Ng (epitope Ng52–65) and has been found to be optimal for…”
MethodResultSelf-citation
Cited by
New insights into atypical Alzheimer's disease in the era of biomarkers
Graff-Radford, J., Yong, K. X. X., Apostolova, L. G., Bouwman, F. H., Carrillo, M., Dickerson, B. C., Rabinovici, G. D., Schott, J. M., Jones, D. T., & Murray, M. E. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30440-3 · Cited by 706
Self-citationForgrave, L. M., Ma, M., Best, J. R., & DeMarco, M. L. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.08.009 · Cited by 177
“In the studies examined, disease mimics for AD included vascular dementia, Lewy body dementia, Parkinson’s disease dementia, idiopathic normal pressure hydrocephalus, and posterior cortical atrophy (Supplementary Material B) [16,23,27,28,33,35,40,43,45,46].”
BackgroundA unifying hypothesis for Alzheimer's disease: from plaques to neurodegeneration
Edwards, F. A. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.03.003 · Cited by 140
Clarke, M. T. M., Brinkmalm, A., Foiani, M. S., Woollacott, I. O. C., Heller, C., Heslegrave, A., Keshavan, A., Fox, N. C., Schott, J. M., Warren, J. D., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0564-2 · Cited by 58
Self-citationNeurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia
Willemse, E. A. J., Sieben, A., Somers, C., Vermeiren, Y., De Roeck, N., Timmers, M., Van Broeckhoven, C., De Vil, B., Cras, P., De Deyn, P. P., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.08.002 · Cited by 34
Metadata
- Authors
- Wellington, H., Paterson, R. W., Suárez‐González, A., Poole, T., Frost, C., Sjöbom, U., Slattery, C. F., Magdalinou, N. K., Lehmann, M., Portelius, E., Fox, N. C., Blennow, K., Zetterberg, H., & Schott, J. M.
- Venue
- Annals of Clinical and Translational Neurology
- Publisher
- Wiley
- Published
- 2018-01-11
- Volume
- 5
- Issue
- 2
- Pages
- 162-171
- ISSN
- 2328-9503 (ISSN-L)
- OpenAlex
- W2783965729
- Cited by
- 34
- References
- 12
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. https://app.cochat.ai/papers/10.1002/acn3.518
- The paper
- Wellington, H., Paterson, R. W., Suárez‐González, A., Poole, T., Frost, C., Sjöbom, U., Slattery, C. F., Magdalinou, N. K., Lehmann, M., Portelius, E., Fox, N. C., Blennow, K., Zetterberg, H., & Schott, J. M. (2018). CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.518
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.